The Latest Breaking News from rapeutic Goods Administration

Cough syrups, lozenges containing pholcodine recalled by Therapeutic Goods Administration over anaphylaxis risk

The recall affects 44 products, including cough syrup and lozenges manufactured by Gold Benadryl, Bisolvon, Codral, TerryWhite, Difflam, Duro-Tuss and others.

ABC News · Feb 28, 2023

Warning over rise in nitrous oxide abuse as service stations sell potentially deadly 'nangs' to teenagers

Canisters of nitrous oxide, known as "nangs" and linked to the death of a Queensland man, are readily available across Australia. But drug experts disagree on what to do.

ABC News · Feb 21, 2023

World-first: Magic mushrooms and ecstasy get the thumbs up for clinical use

The Therapeutic Goods Administration has approved the use of magic mushrooms and ecstasy for mental health treatment.

The New Daily · Feb 5, 2023

'They should be available': Push to allow MDMA, psilocybin for mental health treatment

The Threapeutic Goods Administration is considering whether to reschedule MDMA and psilocybin.

The Canberra Times · Nov 27, 2022

Type 2 diabetics forced to seek alternative treatments as use of Ozempic for weight loss grows

Healthcare workers say they are "gobsmacked" by a shortage of essential treatments for diabetics.

ABC News · Oct 17, 2022

Pfizer COVID vaccine approved for all children aged over six months old

The Therapeutic Goods Administration approves Pfizer's paediatric dose of its COVID vaccine for children aged between six months and five years old.

ABC News · Sep 29, 2022

Interim tick for Pfizer infant booster

The Therapeutic Goods Administration has given provisional approval for Pfizer's COVID-19 booster to be used in children aged six months to five years.

AAP · Sep 29, 2022

Medicinal cannabis companies fined almost $1m by TGA over false treatment claims

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy

The Guardian - AU · Sep 28, 2022

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga · Sep 15, 2022

Blackmores subsidiary kept selling pregnancy vitamins despite hundreds of complaints, ex-employee alleges

Whistleblower says he was instructed to tell customers the products were safe to consume, despite lack of testing evidence

The Guardian - AU · Aug 8, 2022